CSL Of Australia To Begin Trials Of H1N1 Flu Vaccine On Children
This article was originally published in PharmAsia News
Executive SummaryAustralia's CSL said it would begin clinical trials next week on a pediatric version of its H1N1 flu virus, one recommended for use down to the age of six months. The trials are intended to determine the best dosage for children. Children are considered the most susceptible to the virus and in turn spread the infection, particularly to people with poor immune systems. (Click here for more
You may also be interested in...
The $9.7bn acquisition hinges on the small interfering RNA inclisiran, but an ongoing cardiovascular outcomes trial, manufacturing hurdles, and reimbursement challenges provide subjects for concern.
US congressional leaders and medtech industry advocacy group AdvaMed are giving their full-throated endorsement to a US-Mexico-Canada (USMCA) trade agreement announced by the US Trade Representative's Office on 10 December. See what AdvaMed's president and CEO, Scott Whitaker, said about it in a statement here.
FDA seems poised to approve the drug for the orphan eye disease called TED, but remains concerned about labeling for some adverse events.